Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The diagnostic tool will use Thermo Fisher’s next-generation sequencing (NGS)-based Oncomine Dx Target Test to identify HER2 (human epidermal growth factor receptor 2) gene mutations.
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
“Given the current public health crisis, we anticipate pharmaceutical and life sciences manufacturers to consider ‘reshoring’ and expanding operations in the U.S.,” said Joel Bergstein, president of LEG.
Sanofi Pasteur and Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases. The original deal was entered in 2018.
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.
Sarepta Therapeutics entered into a research alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases.
As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Alexander Dettmer as Chief Financial Officer, effective July 1, 2020.